Checkpoint kinase 1 inhibitor + low-dose hydroxyurea efficiently kills BRAF inhibitor- and immune checkpoint inhibitor-resistant melanomas
Details
Publication Year 2024-01,Volume 37,Issue #1,Page 45-50
Journal Title
Pigment Cell & Melanoma Research
Publication Type
Research article
Abstract
Treatment of melanomas with targeted and immunotherapies has proven effective, but resistance to both treatments is a common outcome leaving a high proportion of patients without effective alternative treatment options. Replication stress is a common feature of melanomas, and this is effectively targeted using a combination of checkpoint kinase 1 (CHK1) inhibitor and low-dose hydroxyurea (LDHU). This combination also promotes inflammatory and anti-tumour immune responses in vivo. Melanoma cell lines resistant to BRAF inhibitor (BRAFi) or immune checkpoint inhibitors (ICI) retain their sensitivity to CHK1i + LDHU, with sensitivity similar to that of parental tumours. In vivo, BRAFi-resistant and BRAFi-sensitive parental tumours produce an identical immune response with treatment.
Publisher
Wiley
Keywords
Humans; *Melanoma/pathology; Hydroxyurea/pharmacology/therapeutic use; Proto-Oncogene Proteins B-raf; Checkpoint Kinase 1/therapeutic use; Immune Checkpoint Inhibitors/therapeutic use; Drug Resistance, Neoplasm; Protein Kinase Inhibitors/pharmacology/therapeutic use; Cell Line, Tumor; CHK1 inhibitor; immune response; replication stress; treatment resistance
Department(s)
Laboratory Research
Open Access at Publisher's Site
https://doi.org/10.1111/pcmr.13120
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2024-02-22 12:18:53
Last Modified: 2024-02-22 12:19:18

© 2024 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙